Market Overview

UPDATE: Mizuho Securities Upgrades Cubist Pharmaceuticals on Pending Acquisitions of Optimer and Trius

Related CBST
UPDATE: Credit Suisse Downgrades Cubist Pharmaceuticals On Execution Risk To Global Expansion Of Hospital Franchise
Wedbush Initiates Coverage On Cubist Pharmaceuticals
Is This Superbug Drug Company Right for Your Portfolio? (Fox Business)

In a report published Wednesday, Mizuho Securities analyst Mario Corso upgraded the rating on Cubist Pharmaceuticals (NASDAQ: CBST) from Neutral to Buy, and raised the price target from $50.00 to $77.00.

In the report, Mizuho Securities noted, “We are upgrading our rating on CBST shares to Buy from Neutral with a price target of $77 vs. $50 previously. We have added the pending acquisitions of Optimer and Trius to our financial models, deriving DCF valuations of $77, $96 and $51 in three different revenue/EPS scenarios. Catalysts for achieving our price target are the transactions closing/integration by year end 2013, CBST financial guidance in early 2014, CXA-201 Phase III data by year end, and FDA approval of tedizolid toward mid-2014.”

Cubist Pharmaceuticals closed on Tuesday at $61.59.

Latest Ratings for CBST

Nov 2014Credit SuisseDowngradesOutperformNeutral
Nov 2014SunTrust Robinson HumphreyInitiates Coverage onBuy
Nov 2014WedbushInitiates Coverage onNeutral

View More Analyst Ratings for CBST
View the Latest Analyst Ratings

Posted-In: Mario Corso Mizuho SecuritiesAnalyst Color Upgrades Analyst Ratings


Related Articles (CBST)

Around the Web, We're Loving...

Get Benzinga's Newsletters